Stephen E Fawell

Title: The Innovations of Stephen E. Fawell

Introduction

Stephen E. Fawell is a notable inventor based in Framingham, MA (US). He has made significant contributions to the field of therapeutic nucleic acids and cancer treatment. With a total of 2 patents, Fawell's work has the potential to impact medical science profoundly.

Latest Patents

Fawell's latest patents include a method of enhancing the delivery of a therapeutic nucleic acid. This invention provides methods and compositions for increasing the delivery of nucleic acids into a host by administering a nucleic acid encoding a therapeutic nucleic acid along with an agent that modulates Kupffer cell function in the host. Another significant patent is for antibodies to the human prolactin receptor. This invention provides antibodies that are capable of blocking prolactin binding to the prolactin receptor, inhibiting signaling through the prolactin receptor, and/or inhibiting proliferation of cancer cells induced by prolactin. The patent also includes nucleic acids encoding the antibodies, vectors, and host cells comprising the nucleic acids, along with their various uses.

Career Highlights

Stephen E. Fawell is currently associated with Biogen Idec MA Inc., where he continues to innovate and contribute to advancements in biotechnology. His work is crucial in developing therapies that can enhance patient outcomes.

Collaborations

Fawell has collaborated with notable colleagues such as Brian A. Elenbaas and Matthew B. Jarpe, further enriching his research and development efforts.

Conclusion

Stephen E. Fawell's contributions to the field of biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in therapeutic applications.